Apex Capital Management’s Novartis NVS Stock Holding History

Apex Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$765K	Buy	11,787 +4,017	+52%	+$273K	0.02%	208
2015 Q4	$599K	Buy	7,770 +1,212	+18%	+$96.3K	0.01%	205
2015 Q3	$540K	Buy	6,558 +19	+0.3%	+$1.69K	0.01%	209
2015 Q2	$576K	Sell	6,539 -15	-0.2%	-$1.38K	0.01%	214
2015 Q1	$579K	Buy	6,554 +383	+6%	+$34K	0.01%	212
2014 Q4	$512K	Buy	6,171 +1,651	+37%	+$137K	0.01%	215
2014 Q3	$381K	Hold	4,520	–	–	0.01%	224
2014 Q2	$367K	Buy	4,520 +474	+12%	+$37.3K	0.01%	245
2014 Q1	$308K	Hold	4,046	–	–	0.01%	249
2013 Q4	$291K	Buy	+4,046	New	+$281K	0.01%	236

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Institutional Capital Chicago, Illinois $6.75B AUM 3.44% 1-Year Est. Return

Apex Capital Management's NVS Position: Q1 2016 in Review

Apex Capital Management increased its Novartis (NVS) stake by 52% in Q1 2016, buying an estimated $273K and bringing the position to 11,787 shares worth $765K. The position accounts for 0.02% of the portfolio, ranked #208.

Apex Capital Management first reported a position in NVS in Q4 2013 and has held it in 10 quarters since. 875 funds tracked by Wall St. Rank hold NVS as of Q1 2016.

Apex Capital Management held 11,787 shares of Novartis worth $765K as of Q1 2016.
Apex Capital Management bought 4,017 Novartis shares in Q1 2016, an estimated $273K.
Novartis made up 0.02% of Apex Capital Management's portfolio in Q1 2016, its #208 holding.
Apex Capital Management first reported a position in Novartis in Q4 2013 and has held it in 10 quarters since.
875 funds tracked by Wall St. Rank held Novartis as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.